CYP11B2 and Other metabolic disease: Compounds from the two studied series (7-benzyloxy and 7-aryloxy derivatives) were selected and tested towards CYP11B1 (steroid 11β-hydroxylase, drug target for Cushing’s syndrome, or metabolic disease) [172] and CYP11B2 (aldosterone synthase, drug target for hyperaldosteronism and congestive heart).